The Role of Tumor Mutational Burden in Lung CancerVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.
Dr. Steve O’Day believes a treatment’s value incorporates combination of benefits, side-effects, and cost, stating that if the cost is high, we need to make sure the benefits are huge as well.
Hal Gerstein, MD, details this neurotransmitter’s role in the development of carcinoid tumors and carcinoid syndrome.